GlassScriptPhysician profile
Sukhmani Padda
NPI 1649428053
$92,534.84
in general payments reported to CMS, 2019-2025
19 companies · $19K in 2025
The $19K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,737 · 2020: $7,538 · 2021: $14K · 2022: $9,267 · 2023: $15K · 2024: $22K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Travel and Lodging: $2,182 · Food and Beverage: $754 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,411.75 |
| Travel and Lodging | $2,181.99 |
| Food and Beverage | $753.73 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,401.43 | 2020-2025 | Tagrisso, Imjudo, Imfinzi |
| Regeneron Pharmaceuticals, INC. | $14,081.55 | 2023-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $6,241.87 | 2019-2022 | |
| Pfizer INC. | $5,705.32 | 2019 | |
| Daiichi Sankyo INC. | $5,670.00 | 2023-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $4,398.75 | 2024 | Alunbrig |
| Eli Lilly and Company | $4,116.12 | 2024 | Retevmo |
| E.R. Squibb & Sons, L.L.C. | $4,039.22 | 2022-2024 | |
| Astrazeneca Uk Limited | $3,614.99 | 2022-2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $3,464.50 | 2023-2024 | |
| Genzyme Corporation | $2,916.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $2,781.00 | 2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $2,675.55 | 2021-2023 | |
| Blueprint Medicines Corporation | $2,137.50 | 2020 | |
| Genentech USA, INC. | $2,044.52 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,892.84 | 2022-2025 | Rybrevant |
| Janssen Global Services, LLC | $1,890.00 | 2021 | |
| Amgen INC. | $1,463.68 | 2023-2025 | Lumakras |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhmani Padda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.